Evonetix Granted Patent for Binary Assembly Method for Gene Synthesis
Drug Discovery Today
MAY 10, 2022
IP covers novel method for assembly and error removal in DNA synthesis on silicon chips.
Sat.May 07, 2022 - Fri.May 13, 2022
113 
Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers
Drug Channels
MAY 10, 2022
Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB. You can find links to each company’s data below. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021.
New patent expiration for Purdue Pharma drug TARGINIQ
Drug Patent Watch
MAY 9, 2022
Annual Drug Patent Expirations for TARGINIQ Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are fifteen patents protecting this drug. Drug patent…. The post New patent expiration for Purdue Pharma drug TARGINIQ appeared first on DrugPatentWatch - Make Better Decisions.
Tactics for Agile in Biopharma Research & Development
EG Life Sciences
MAY 12, 2022
As we have provided several blog posts and hosted Lean Coffees about the potential of Agile in Biopharma, a theme has emerged – the crucial role of communication in implementing Agile. We have discussed how to work with individual team members, from scientists who may be skeptical of Agile practices , to team members who are feeling "transparency anxiety," to leaders who haven't entirely bought in to the project.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’
Sygnature Discovery
MAY 9, 2022
Sygnature are thrilled to announce that we have embarked on a 3-year collaboration agreement with Iktos , an innovative technology company specialising in Artificial Intelligence (AI) for new drug design. We’ll be deploying Makya™ to facilitate rapid and efficient design of novel compounds and accelerate hit-to-lead/lead optimisation, further optimizing our integrated drug discovery capabilities and improving on how we serve our customers.
Opportunities to Improve Critical Medication Access in Oncology
Drug Channels
MAY 13, 2022
Today’s guest post comes from Shawn Seamans, Chief Commercial Officer at CoverMyMeds. Shawn discusses the unique challenges cancer patients face in accessing, affording, and adhering to treatment. He explains how patient-centric technology, combined with access to caring experts, can alleviate these challenges. Read more about access, affordability, and adherence opportunities for oncology patients in the CoverMyMeds 2022 Medication Access Report: Oncology Edition.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
More Trending
WHO delivers 20 ambulances to Ukraine
The Pharma Data
MAY 9, 2022
To support emergency health needs in Ukraine, World Health Organization (WHO) today gave 20 all-terrain ambulances able to function in even the most damaged and inaccessible areas to the Ministry of Health of Ukraine. “We bring not just supplies but support based on your needs. Today we are handing to you 20 ambulances, along with generators and blood refrigerators to hospitals wherever they are needed.” said Dr Tedros Adhanom Ghebreyesus, the WHO Director-General handing over the keys to
Sex, Drugs, Booze, and Contributory Negligence
Drug & Device Law
MAY 11, 2022
Sometimes we write about a case because it is important. Sometimes we write about a case because it is novel. And sometimes we write about a case simply because it is fun. Nixon v. Kysela Pere et Fils, Ltd. et al. , 2022 U.S. Dist. LEXIS 48067 (W.D. Va. March 17, 2022), tumbles into that last category. The defendant Kysela Pere et Fils, LTD. (“the Company”), was an international wine and spirits distributor.
Informa Connect’s Hub and Specialty Pharmacy Models East
Drug Channels
MAY 9, 2022
Informa Connect’s Hub and Specialty Pharmacy Models East. Delivered as a Hybrid Event. June 28-30, 2022 | Sheraton Parsippany | Parsippany, NJ www.informaconnect.com/hub-specialty-pharmacy. Drug Channels readers will save 10% off the current registration rate when they use code 22DC10*. This important event convenes key stakeholders including manufacturers, specialty pharmacies, hub providers and more for unrivaled collaboration to leverage innovation and optimize access.
Which pharmaceutical companies have the most SPCs in Lithuania?
Drug Patent Watch
MAY 12, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Lithuania. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Lithuania? appeared first on DrugPatentWatch - Make Better Decisions.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Recurring brain tumor growth is halted with new drug
The Pharma Data
MAY 9, 2022
When a non-metastatic brain tumor – a meningioma – recurs after surgery and radiation treatment, a patient is out of options. No drugs are approved for these aggressive tumors, which occur in up to 20% of cases and can lead to patient disability or even death. But now Northwestern Medicine scientists, in an international collaboration with scientists at the University of California, San Francisco and the University of Hong Kong, have identified a drug that inhibits growth of the most
Fourth Circuit Upholds Restrictions on Plaintiff Lawyer Advertising in West Virginia
Drug & Device Law
MAY 10, 2022
We want to start by emphasizing the word restrictions. The law at issue in West Virginia was not a ban on plaintiff lawyer advertising, nor could it be. Since Bates v. State Bar of Arizona , 433 U.S. 350 (1977), the First Amendment’s protection of truthful and non-misleading commercial speech extends to lawyers. Lawyers, like professionals offering other services, can advertise and such advertising can serve the legitimate purpose of helping an individual determine if they have a legal proble
Which pharmaceutical companies have the most emulsion dosed drugs?
Drug Patent Watch
MAY 11, 2022
This chart shows the pharmaceutical companies with the most emulsion dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most emulsion dosed drugs…. The post Which pharmaceutical companies have the most emulsion dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
New patent for COVIS drug MAKENA
Drug Patent Watch
MAY 11, 2022
Annual Drug Patent Expirations for MAKENA Makena is a drug marketed by Covis and is included in one NDA. It is available from two suppliers. There are nine patents protecting…. The post New patent for COVIS drug MAKENA appeared first on DrugPatentWatch - Make Better Decisions.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
New patent for COVIS drug MAKENA PRESERVATIVE FREE
Drug Patent Watch
MAY 11, 2022
Annual Drug Patent Expirations for MAKENA+PRESERVATIVE+FREE Makena Preservative Free is a drug marketed by Covis and is included in one NDA. It is available from two suppliers. The generic ingredient…. The post New patent for COVIS drug MAKENA PRESERVATIVE FREE appeared first on DrugPatentWatch - Make Better Decisions.
New patent for COVIS drug MAKENA (AUTOINJECTOR)
Drug Patent Watch
MAY 11, 2022
Annual Drug Patent Expirations for MAKENA+%28AUTOINJECTOR%29 Makena (autoinjector) is a drug marketed by Covis and is included in one NDA. It is available from two suppliers. There are nine patents…. The post New patent for COVIS drug MAKENA (AUTOINJECTOR) appeared first on DrugPatentWatch - Make Better Decisions.
New patent for Bausch drug ARAZLO
Drug Patent Watch
MAY 11, 2022
Annual Drug Patent Expirations for ARAZLO Arazlo is a drug marketed by Bausch and is included in one NDA. It is available from one supplier. The generic ingredient in ARAZLO…. The post New patent for Bausch drug ARAZLO appeared first on DrugPatentWatch - Make Better Decisions.
Which pharmaceutical companies have the greatest global patent coverage?
Drug Patent Watch
MAY 10, 2022
This chart shows the pharmaceutical companies with patents in the most countries. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the greatest global patent coverage? appeared first on DrugPatentWatch - Make Better Decisions.
Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
New patent expiration for Optinose Us drug XHANCE
Drug Patent Watch
MAY 10, 2022
Annual Drug Patent Expirations for XHANCE Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. There are thirteen patents protecting this drug. XHANCE drug…. The post New patent expiration for Optinose Us drug XHANCE appeared first on DrugPatentWatch - Make Better Decisions.
Which pharmaceutical companies have the most drug patents in Sweden?
Drug Patent Watch
MAY 8, 2022
This chart shows the pharmaceutical companies with the most patents in Sweden. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Sweden? appeared first on DrugPatentWatch - Make Better Decisions.
Which pharmaceutical companies have the most SPCs in France?
Drug Patent Watch
MAY 7, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in France. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in France? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Expirations for the Week of May 8, 2022
Drug Patent Watch
MAY 11, 2022
TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) Purdue pharma lp Patent: 9,511,066 Expiration: May 10, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence…. The post Drug Patent Expirations for the Week of May 8, 2022 appeared first on DrugPatentWatch - Make Better Decisions.
Which pharmaceutical drugs have the most drug patents in South Africa?
Drug Patent Watch
MAY 9, 2022
This chart shows the drugs with the most patents in South Africa. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical drugs have the most drug patents in South Africa? appeared first on DrugPatentWatch - Make Better Decisions.
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
The Pharma Data
MAY 9, 2022
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE ® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.
Pennsylvania Also Rejects Educational Malpractice, and Thus Duty-To-Train Claims
Drug & Device Law
MAY 9, 2022
We have posted twice before about decisions that reject duty-to-train claims under the rubric of “educational malpractice.” Now Pennsylvania has joined the party. Grady v. Aero-Tech Services, Inc. , 2022 WL 683720 (Pa. Super. March 8, 2022), an unpublished, but citable, decision of Pennsylvania’s major intermediate appellate court, applied Pennsylvania’s prior precedents that reject educational malpractice claims specifically to specialized product-related training.
Pelvic Mesh Remand Cases Continue To Stall
Drug & Device Law
MAY 12, 2022
We do not care much about car racing. Sure, we have seen some parts of some races on television, had toy racecars in our remote youth, and have craned our necks to see a few fancy “street legal” versions zooming past. However, we have never attended a race in person and do not follow any driver or team. When we heard a presentation last week from a Formula 1 executive, we paid it about as much attention as we pay most presentations in a room full of hundreds of lawyers.
Design Defect Claim Dismissed in W.D.N.Y. Fosamax Case
Drug & Device Law
MAY 13, 2022
We write today from a room in a rehabilitation facility, where we just shared the Drug and Device Law Dowager Countess’s lunch. The Countess, nearly 88, plunged down a flight of eight concrete stairs 12 days ago and managed to emerge with three broken ribs (one in two places) and no other injuries. A painful injury with a long recovery time, but miraculous all in all.
Let's personalize your content